ALKEON CAPITAL MANAGEMENT LLC 13D and 13G filings for Akero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-13 09:45 am Sale |
2024-09-30 | 13G | Akero Therapeutics, Inc. AKRO |
ALKEON CAPITAL MANAGEMENT LLC | 3,325,004 4.800% |
-439,216 (-11.67%) |
Filing |
| 2024-02-13 6:30 pm Purchase |
2023-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
ALKEON CAPITAL MANAGEMENT LLC | 3,764,220 6.800% |
520,305 (+16.04%) |
Filing |
| 2023-02-13 10:54 am Purchase |
2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
ALKEON CAPITAL MANAGEMENT LLC | 3,243,915 6.900% |
764,244 (+30.82%) |
Filing |
| 2022-02-11 8:25 pm Purchase |
2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
ALKEON CAPITAL MANAGEMENT LLC | 2,479,671 7.100% |
192,041 (+8.39%) |
Filing |
| 2021-02-11 4:54 pm Purchase |
2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO |
ALKEON CAPITAL MANAGEMENT LLC | 2,287,630 6.600% |
2,287,630 (New Position) |
Filing |